-
Mashup Score: 9
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 9
The four-year grant is for $2.5 million and will fund a project titled, “Immune elimination of drug-tolerant persister cells in oncogene-driven lung cancer.”
Source: www.docwirenews.comCategories: General Medicine News, Partners & KOLsTweet-
📰 ICYMI: A project led by @DavidBarbie8 of @DFarberThoracic, @DanaFarber is the first to receive the @IASLC @lcrf_org Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: https://t.co/LS9wbbN5In #lcsm #LCAM #LungCancer https://t.co/2YiinZ1qN8
-
📰 ICYMI: A project led by @DavidBarbie8 of @DFarberThoracic, @DanaFarber is the first to receive the @IASLC @lcrf_org Team Science Research Grant on the Next Step in the Cure of Oncogene-Driven Lung Cancers Award. ➡️ Learn more: https://t.co/LS9wbbN5In #lcsm #LCAM #LungCancer https://t.co/2YiinZ1qN8